South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol
Recruiting
Phase 4
Interventional Study
Arsenic Trioxide
Childhood ALL
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 1 – 14
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 210 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In recent years, the prognosis of pediatric relapsed ALL patients has improved, but the 5-year OS of patients with first recurrence is still less than 50%. A number of in vitro studies have shown that arsenic trioxide (ATO) can selectively inhibit the growth and induce apoptosis in a variety of leukemia cell lines, suggesting that ATO as a synergist combined with other common chemotherapy drugs ma…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* B or T cell type;
* the first recurrence;
* the risk stratification was medium or high risk.
Exclusion Criteria:
* mature B cell leukemia;
* acute mixed phenotype leukemia;
* patients with positive BCR/ABL fusion gene;
* the second tumor
* definite CML blast crisis;
* ALL wi…
Contacts